MBX Biosciences, Inc. MBX
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide ("PEP") platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $79.2M | $57.4M | $28.5M | — |
| SG&A | $18.9M | $10.8M | $6.8M | — |
| Total operating expenses | $98.1M | $68.2M | $35.3M | — |
| Operating income | -$98.1M | -$68.2M | -$35.3M | — |
| Pre-tax income | -$87.0M | -$61.9M | -$32.6M | — |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$87.0M | -$61.9M | -$32.6M | — |
| EPS, basic | -2.38 | -5.82 | -31.96 | — |
| EPS, diluted | -2.38 | -5.82 | -31.96 | — |
| Shares, diluted (wtd. avg.) | 36.5M | 10.6M | 1.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $75.3M | $49.4M | $30.5M | — |
| Short-term investments | $298.4M | $212.8M | $50.2M | — |
| Total current assets | $381.5M | $267.3M | $83.5M | — |
| Property, plant and equipment | $2.7M | $1.1M | $439.0K | — |
| Total assets | $385.1M | $268.5M | $84.2M | — |
| Accounts payable | $3.0M | $5.3M | $1.4M | — |
| Total current liabilities | $15.5M | $11.1M | $3.9M | — |
| Total liabilities | $15.9M | $11.1M | $4.3M | — |
| Retained earnings | -$224.5M | -$137.5M | -$75.6M | — |
| Total equity | $369.2M | $257.4M | -$72.5M | -$42.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$79.9M | -$54.7M | -$32.0M | — |
| Depreciation and amortisation | $248.0K | $244.0K | $157.0K | — |
| Stock-based compensation | $8.7M | $5.2M | $2.0M | — |
| Capital expenditure | $1.9M | $874.0K | $129.0K | — |
| Investing cash flow | -$83.7M | -$160.6M | -$30.9M | — |
| Financing cash flow | $189.6M | $234.1M | $69.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-103121.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Net income | — | -$32.6M | -$61.9M | -$87.0M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |